Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]

ClinicalTrials.gov ID: NCT00785954

Public ClinicalTrials.gov record NCT00785954. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Inhibition of Delta-protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction

Study identification

NCT ID: NCT00785954
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: KAI Pharmaceuticals; Industry
Enrollment: 1,180 participants

Conditions and interventions

Conditions

Interventions

KAI-9803 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2008
Primary completion: Jun 30, 2010
Completion: Apr 30, 2011
Last update posted: Sep 1, 2011

2008 – 2011

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Huntsville	Alabama	35801	—
Not listed	Escondido	California	92025	—
Not listed	Torrance	California	90509	—
Not listed	Tampa	Florida	33613	—
Not listed	Atlanta	Georgia	30309	—
Not listed	Downers Grove	Illinois	60515	—
Not listed	Lombard	Illinois	60148	—
Not listed	Peoria	Illinois	61602	—
Not listed	Valparaiso	Indiana	46383	—
Not listed	Omaha	Nebraska	68131	—
Not listed	Williamsville	New York	14221	—
Not listed	Greensboro	North Carolina	27410	—
Not listed	High Point	North Carolina	27262	—
Not listed	Zanesville	Ohio	43701	—
Not listed	Oklahoma City	Oklahoma	77030	—
Not listed	Beaver	Pennsylvania	15009	—
Not listed	Danville	Pennsylvania	17822	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 109 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00785954, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2011 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00785954 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →